Patrícia Silva, PhD, director of science content —

New data from Phase 3 clinical studies of Genentech’s Esbriet (pirfenidone), a drug developed for the treatment of pulmonary fibrosis (PF), showed the treatment’s efficacy over time. The data presentation, the “Effect of continued treatment with pirfenidone following a clinically meaningful decline in percent predicted forced vital capacity in…

miRagen Therapeutics, Inc., a biopharmaceutical company dedicated to the development of pioneering therapies based on microRNAs, recently announced the start of a Phase 1 clinical trial on the company’s product MRG-201 developed as a therapy for fibrotic conditions. MicroRNAs (miRNAs) are small RNAs that act as master regulators of…

Boehringer Ingelheim recently announced new positive data on the company’s FDA-approved therapy OFEV® (nintedanib) for the treatment of idiopathic pulmonary fibrosis (IPF). The results were presented at the Pulmonary Fibrosis Foundation’s PFF Summit 2015 in Washington, D.C. OFEV is a tyrosine-kinase inhibitor (TKI) that targets growth factors, such as the vascular endothelial…

The nonprofit phaware global association (phaware), an organization focused on raising awareness of pulmonary hypertension, has developed a new mobile app (phaware365) to help achieve its goal globally through an innovative and engaging strategy. Pulmonary hypertension (PH) is a life-threatening cardiopulmonary disorder characterized by an abnormally high blood pressure in the…

Genentech, a member of the Roche Group, recently presented two abstracts on the company’s product Esbriet (pirfenidone), an oral drug developed for the treatment of pulmonary fibrosis (PF), at the American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada. Both abstracts were…

Esbriet (pirfenidone, Genentech) is an anti-fibrotic drug developed as a therapy for pulmonary fibrosis (PF), and was one of the first two drugs to receive approval for PF treatment in the United States. New data on Esbriet was recently presented by Dr. Steven Nathan, Medical Director, Advanced Lung Disease…

The Pulmonary Fibrosis Foundation (PFF) recently announced that the number of scientific poster presentations on idiopathic pulmonary fibrosis (IPF) and interstitial lung diseases (ILD) to be displayed at the upcoming PFF Summit 2015: From Bench to Bedside in Washington, D.C., reached a record. The PFF Summit 2015: From…

The Pulmonary Fibrosis Foundation (PFF) recently announced in a press release a five-year collaboration with Boehringer Ingelheim to support PFF programs dedicated to the improvement of the clinical outcome in patients with pulmonary fibrosis (PF), increase awareness about the disease, and offer advance care, disease education and…

The Pulmonary Fibrosis Foundation (PFF), an organization whose goal is to raise awareness, offer disease education, advance care, and fund research in the field of pulmonary fibrosis (PF), announced in a press release that Genentech, a biotechnology company part of the Roche Group, will assume the role of Founding…

The American College of Chest Physicians Annual Meeting (CHEST 2015), held Oct. 24–28 in Montreal, Canada, included a breakfast symposium where a panel of experts shared practical tips to help clinicians assess, diagnose, and manage idiopathic pulmonary fibrosis (IPF) and co-morbidities linked to the disease. Dr. Timothy Whelan, associate professor…